Medical Services Advisory Committee - Applications Considered
- 1192.3 – Reduction of mitral regurgitation through tissue approximation, using transvenous/transeptal techniques (resubmission)
- 1344.2 - Assessment of foot and ankle services by podiatric surgeons (resubmission)
- 1420.1 - Extracorporeal photopheresis for treatment of cutaneous T-cell lymphoma (resubmission)
- 1429.1 - Targeted Intraoperative Radiotherapy (T-IORT) for early-stage breast cancer (resubmission)
- 1466 - Vertebroplasty for severely painful osteoporotic vertebral fractures
- 1485.1 - Sentinel Lymph Node Biopsy for intermediate thickness melanoma (resubmission)
- 1553 - Transmural fixation of aortic endograft adjunct to endovascular aneurysm repair using helical anchors
- 1564 - Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Review of immunoglobulin use
- 1566 - Myasthenia Gravis - Review of immunoglobulin use
- 1570 - PD-L1 (Programmed death ligand 1) immunohistochemistry (IHC) testing for access to atezolizumab as first-line therapy for patients with locally advanced or metastatic triple-negative breast cancer (TNBC)
- 1572 - Diagnosis of hypertension using ambulatory blood pressure monitoring in patients with clinic blood pressure ≥ 140/90mmHg and ≤ 180/110mmHg
- 1607 - 17p deletion testing for access to acalabrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia
- 1621 - Amendment to MBS Item 73344 for c-ROS proto-oncogene 1 (ROS1) fluorescence in situ hybridisation (FISH) testing to identify ROSI to determine patient eligibility for entrectinib under the Pharmaceutical Benefits Scheme (PBS)